Material matter: Korean MFDS approves the phase 3 trial plan for HCP18034
DART
Hanmi Pharm. Co., Ltd.
Filed May 29, 2026 KST · Filing
· receipt 20260529802039
kstock has not written this one up.
The title above is a translation of the Korean form name; the filing itself is on DART, in
Korean.
Read the original on DART ↗Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory
Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항 (HCP18034 개발을 위한 식약처(MFDS) 제3상 임상시험 계획 승인)